ISPOR EXPANDS SCIENTIFIC STAFF BY ADDITION OF CHIEF SCIENCE OFFICER

Published Sep 1, 2015
Princeton, NJ, USA - The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce it is recruiting for a Senior Director & Chief Science Officer, a new position reporting to the Chief Executive Officer & Executive Director.  This position offers an exceptional opportunity to contribute to the continued success of an internationally recognized health economics and outcomes research society. ISPOR’s knowledge products and services include conferences, education, journals, publications, guidelines, and tools used by thousands of global health economists and health care decision makers annually. By focusing on member input and construction of the consensus view of the appropriate path for advancing HEOR science, the successful candidate will develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. The successful candidate will bring to ISPOR extensive experience.  “We look forward to hearing from senior level candidates with deep professional experience, well versed in health economics and outcomes research as well as a passion for ISPOR.  We encourage applications from the global community based on the following position description”, said Nancy Berg, ISPOR CEO & Executive Director. Further details on the position and application details are available at:  ISPOR eJobs Employment Center.

Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×